Study of the relative bioavailability of a multisource formulation of sulfamethoxazole regarding the drug reference
Descripción del Articulo
Objective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole /...
Autores: | , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2016 |
Institución: | Universidad de San Martín de Porres |
Repositorio: | Horizonte médico |
Lenguaje: | español |
OAI Identifier: | oai:horizontemedico.usmp.edu.pe:article/465 |
Enlace del recurso: | https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/465 |
Nivel de acceso: | acceso abierto |
Materia: | Biodisponibilidad relativa Bioequivalencia Sulfametoxazol Medicamento multifuente Medicamento de referencia Relative bioavailability Bioequivalence Sulfamethoxazole Multisource drug Drug reference |
Sumario: | Objective: To determine the relative bioavailability of an oral formulation of multisource sulfamethoxazole 200 mg / 5 ml respect to the reference formulation Oryctolagus cuniculus L (albino rabbits). Material and methods: The samples studied consisted of 25 vials of suspension of sulfamethoxazole / trimethoprim multisource 200 mg: 40 mg / 5 ml T1 with the letter assigned to the batch 11070674; and as a reference (R) 25 flasks Bactrim suspension of 200 mg: 40 mg / 5 ml, RJ0774 batch. The protocol consisted of a single oral dose of 100 mg / kg of sulfamethoxazole 200 mg / 5 ml of each of the formulations to 12 albino rabbits after a 12 hour fasting, through an open design in two cross periods (T / R), randomized, double-blind study with a greater range of 5 half-lives between each administration, later to determine plasma concentrations of the drug in default until 12 hours by means of a spectrophotometric method periods of time colorimetric diazotization. With the data of plasma, bioavailability curves were constructed, including the area under the curve (ABCo-12h , ABCo-∞ ), Cmax and tmax were determined. Results: According to statistical analysis for bioequivalence, it was found: ABCo-12h T1 / ABCo-12h R CI 90% from 0.873 to 1.021, AUCo-∞ T1 / AUCo-∞ R 90% CI 0.868 to 1.032 and Cmax T1 / Cmax R CI 90% 0,866- 1,045. Conclusions: The values of multisource sulfamethoxazole found are within the acceptable range of bioequivalence proposed by WHO and the FDA(0.80-1.25), demonstrating the bioequivalence of multisource T1 respect to the reference. |
---|
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).